Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer

SpringerPlus

Table 3 Cox proportional hazard stratified based on a) ER-status, and b) menopausal status relating BC patients with coexisting AD-HS to BC patients without

a) Number of patients included in the analysis N=332 and N=695, respectively
	Patients with ER-negative tumors				Patients with ER-positive tumors
	HR	95% CI for HR		p-value	HR	95% CI for HR		p-value
		Lower	Upper			Lower	Upper
AD-HS	0.53	0.30	0.96	0.036	0.98	0.70	1.37	0.909
T1	1.00	Ref	Ref		1.00	Ref	Ref
T2	1.30	0.95	1.77	0.097	1.60	1.26	2.03	<0.001
T3	2.62	1.69	4.08	<0.001	1.97	1.33	2.91	0.001
T4	3.86	0.91	16.42	0.067	-	-	-	-
N0	1.00	Ref	Ref		1.00	Ref	Ref
N1	1.63	1.17	2.27	0.004	1.28	1.00	1.64	0.054
N2	2.29	1.51	3.49	<0.001	1.38	0.98	1.93	0.064
N3	2.72	1.54	4.81	0.001	2.61	1.68	4.06	<0.001
Screening	0.59	0.27	1.26	0.174	0.75	0.51	1.11	0.149
b) Number of patients included in the analysis N=499 and N=959, respectively
	Premenopausal BC patients				Postmenopausal BC patients
	HR	95% CI for HR		p-value	HR	95% CI for HR		p-value
		Lower	Upper			Lower	Upper
AD-HS	0.63	0.38	1.04	0.073	1.02	0.77	1.34	0.898
T1	1.00	Ref	Ref		1.00	Ref	Ref
T2	1.22	0.91	1.65	0.190	1.48	1.23	1.78	<0.001
T3	3.29	2.16	5.01	<0.001	1.73	1.25	2.39	0.001
T4	-	-	-	-	1.68	0.53	5.31	0.377
N0	1.00	Ref	Ref		1.00	Ref	Ref
N1	1.54	1.11	2.13	0.009	1.58	1.28	1.95	<0.001
N2	2.72	1.85	4.00	<0.001	1.84	1.43	2.39	<0.001
N3	3.63	2.07	6.36	<0.001	2.95	2.15	4.05	<0.001
Screening	0.66	0.29	1.50	0.319	0.76	0.59	0.97	0.030

Both models are adjusted for age at BC diagnosis, T- and N-status of the tumor, and screening simultaneously.
T1 and N0 were reference values for respective category.